CD8A and cancer: Major players in the anti-cancer immune response are the CD8+ cytotoxic T lymphocytes (CTLs), which specifically recognize peptides derived from cancer-specific or over-expressed proteins when presented by the Major Histocompatibility Complex (MHC) class I molecules on the surface of the transformed cells or cross-presented by dendritic cells.